The Bland Company

Executive Summary

The Bland Company is a UK-based biotech platform specializing in advanced drug delivery systems for biologics, including proteins, peptides, and nucleic acids. Founded in 2019 and headquartered in London, the company leverages proprietary technologies for targeted delivery, controlled release, and enhanced stability, aiming to improve the efficacy and safety of biologic therapeutics. Operating at the platform stage, The Bland Company partners with therapeutic developers to reformulate existing drugs and enable new modalities, serving the immunology, oncology, and metabolic disease sectors. While still private and pre-revenue, the company's innovative delivery platforms address key challenges in biologic development, such as poor stability and off-target effects, positioning it as a potential enabler for next-generation therapies. With a growing team of 50-200 employees and a focus on high-value therapeutic areas, The Bland Company is poised to attract strategic partnerships and investment.

Upcoming Catalysts (preview)

• Q3 2026Announcement of first major partnership with a top-tier pharma for reformulation of a biologic55% success
• Q4 2026Publication of preclinical data demonstrating superiority of delivery platform in oncology model70% success
• Q2 2026Closing of Series B funding round (target ~$30M) to expand platform capabilities60% success